PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104537
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104537
Immunoassay for Neurological Biomarkers Market size was valued at USD 1,090.3 Million in 2025, expanding to a CAGR of 9.1% from 2026 to 2033.
Immunoassays for neurological biomarkers are advanced analytical testing methods that leverage highly specific antigen-antibody interactions to identify and quantify biomarkers linked to neurological disorders. These assays play a critical role in the diagnosis, disease monitoring, prognosis, and therapeutic assessment of various neurological conditions, enabling clinicians and researchers to gain valuable insights on diseases.
Immunoassay for Neurological Biomarkers Market- Market Dynamics
Growing prevalence of neurological disorders and advancement in biomarker testing are expected to propel market demand
The global immunoassay for neurological biomarkers market is experiencing significant growth owing to the rising prevalence of neurodegenerative and neurological disorders worldwide. The market is driven by the increase in prevalence of diseases like Alzheimer's disease, sclerosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and various types of dementia. Immunoassays are often essential in the early detection of disease-associated biomarkers, often preceding the development of major clinical symptoms. Continued improvements in assay sensitivity, the ability to perform multiplex testing and detection of blood-based biomarkers are also driving market growth. Market demand is also driven by the growing availability of minimally invasive testing.
Another important factor driving the market growth is the continuous development of immunoassay technologies and the increasing acceptance of precision medicine in the neurological care. Growing investments in neuroscience studies, biomarker discovery and validation programs and companion diagnostic development are encouraging innovation across the industry. Key market trends include increasing commercialization of blood-based diagnostic tests for Alzheimer's disease, multiple immunoassay platforms to analyze multiple biomarkers from a single sample. These innovations are improving diagnostic accuracy, simplifying clinical decision making, reducing testing complexity and enabling broader implementation of neurological biomarker testing in healthcare facilities, diagnostic laboratories etc. Furthermore, rising investments in the research of neuroscience, biomarker tests are also augmenting the market growth. Thus, sophisticated immunoassays are increasingly important for disease stratification in neurological disorders.
The Global Immunoassay for Neurological Biomarkers Market is segmented on the basis of Product Type, Disease, End User, and Region.
The market is divided into four categories based on Disease: Alzheimer's disease, Parkinson's disease, multiple sclerosis, and others. Alzheimer's disease accounts for the substantial share of the immunoassay for neurological biomarkers market owing to its high prevalence across the globe. Further, increasing healthcare spending and developments immunoassay technologies is accelerating Alzheimer disease segment demand.
Immunoassay for Neurological Biomarkers Market- Geographical Insights
The Asia-Pacific region is one of the fastest growing markets for immunoassays in neurological biomarker testing. The growth is driven by increasing healthcare spending, rising prevalence of neurological diseases, and continued investment in diagnostic and research infrastructure. China, Japan, South Korea and India are all actively developing their neuroscience study programs, improving clinical diagnostic capabilities and access to cutting-edge biomarker testing technologies. The market growth is also driven by the region's rapidly aging population, rising awareness about neurodegenerative diseases, and increasing focus on early diagnosis and preventive healthcare. North America continues to be a leading market, supported by a strong healthcare infrastructure, significant investment in neurological research, and early adoption of advanced diagnostic solutions. The presence of leading biotechnology and diagnostics companies, strong government and private-sector funding, and growing utilization of biomarker-based testing for conditions such as Alzheimer's disease and Parkinson's disease continue to support market expansion across the region.
U.S. Immunoassay for Neurological Biomarkers Market- Key Insights
The United States is an important market for immunoassays for neurological biomarkers testing, due to the country's strong biotechnology industry, a well-developed neuroscience study environment and early adoption of innovative diagnostic solutions. The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurodegenerative diseases is driving the demand for highly accurate and minimally invasive biomarker-based diagnostic solutions. Healthcare organizations and clinicians are increasingly using biomarker testing to help detect disease earlier and improve diagnosis.
The immunoassay for neurological biomarkers market is characterized by intense competition, with major diagnostics manufacturers, life sciences companies, and biotechnology firms focusing on enhancing assay accuracy. Industry participants are making significant investments in research and development to identify novel neurological biomarkers, improve analytical performance, etc. In addition, strategic partnerships and collaborations with pharmaceutical companies, research institutes is fueling market growth. These strategic initiatives are helping market players strengthen their competitive positions while expanding the clinical utility of neurological biomarker testing.
In January 2025, Roche expanded its neurological diagnostics portfolio by introducing advanced blood-based biomarker testing solutions aimed at improving the early identification, diagnosis, etc.
In June 2025, Abbott Laboratories boosted its immunodiagnostics portfolio through enhancements to automated neurological biomarker testing capabilities, aiding improved laboratory efficiency, and advanced diagnostic solutions.